NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing

Published:October 21, 2021DOI:


      • The use of genomic testing increased prostate cancer risk designations in an African American cohort
      • OncotypeDX may predict higher risk than do National Comprehensive Cancer Network guidelines
      • Genomic testing may help risk stratify men with low and intermediate risk prostate cancer
      • Genomic testing in men of African descent may better inform prostate cancer treatment plans



      To assess the utility of genomic testing in risk-stratifying Black patients with low and intermediate risk prostate cancer.


      We retrospectively identified 63 Black men deemed eligible for active surveillance based on National Comprehensive Cancer Network (NCCN) guidelines, who underwent OncotypeDx Genomic Prostate Score testing between April 2016 and July 2020. Nonparametric statistical testing was used to compare relevant features between patients reclassified to a higher NCCN risk after genomic testing and those who were not reclassified.


      The median age was 66 years and median pre-biopsy PSA was 7.3. Initial risk classifications were: very low risk: 7 (11.1%), low risk: 24(38.1%), favorable intermediate risk: 31(49.2%), and unfavorable intermediate risk: 1 (1.6%). Overall, NCCN risk classifications after Genomic Prostate Score testing were significantly higher than initial classifications (P=.003, Wilcoxon signed-rank). Among patients with discordant risk designations, 28(28/40, 70%) were reclassified to a higher NCCN risk after genomic testing. A pre-biopsy prostate specific antigen of greater than 10 did not have significantly higher odds of HBR (OR:2.16 [95% CI: 0.64,7.59, P=.2). Of favorable intermediate risk patients, 20(64.5%) were reclassified to a higher NCCN risk. Ultimately, 18 patients underwent definitive treatment.


      Incorporation of genomic testing in risk stratifying Black men with low and intermediate-risk prostate cancer resulted in overall higher NCCN risk classifications. Our findings suggest a role for increased utilization of genomic testing in refining risk-stratification within this patient population. These tests may better inform treatment decisions on an individualized basis.


      PCa (prostate cancer), AS (active surveillance), NCCN (National Comprehensive Cancer Network), GPS (Genomic Prostate Score), PSA (prostate specific antigen), PSAD (prostate specific antigen density), PIRADS (Prostate Imaging Reporting and Data System), VLR (very low risk), LR (low risk), UIR (unfavorable intermediate risk), FIR (favorable intermediate risk), HR (high risk), DRE (digital rectal exam), RP (radical prostatectomy), RT (radiation therapy), mpMRI (multiparametric magnetic resonance imaging)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Deka R
        • Courtney PT
        • Parsons JK
        • et al.
        Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance.
        JAMA. 2020; 324: 1747-1754
        • Pietzak EJ
        • Van Arsdalen K
        • Patel K
        • Malkowicz SB
        • Wein AJ
        • Guzzo TJ.
        Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer.
        Urology. 2015; 85: 436-440
        • Dess RT
        • Hartman HE
        • Mahal BA
        • et al.
        Association of black race with prostate cancer-specific and other-cause mortality.
        JAMA Oncol. 2019; 5: 975-983
        • Chornokur G
        • Dalton K
        • Borysova ME
        • Kumar NB.
        Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.
        Prostate. 2011; 71: 985-997
      1. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2020). Accessed August 12, 2020

        • Mahal BA
        • Butler S
        • Franco I
        • et al.
        Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015.
        JAMA. 2019; 321: 704-706
        • Sundi D
        • Ross AE
        • Humphreys EB
        • et al.
        African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?.
        J Clin Oncol. 2013; 31: 2991-2997
        • Cullen J
        • Rosner IL
        • Brand TC
        • et al.
        A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer.
        Eur Urol. 2015; 68: 123-131
      2. Interpreting your oncotype DX Genomic Prostate Score Results.OncotypeIQ 2020 Available at:, accessed September 1, 2020.

        • Kızılay F
        • Çelik S
        • Sözen S
        • et al.
        Correlation of Prostate-Imaging Reporting and Data Scoring System scoring on multiparametric prostate magnetic resonance imaging with histopathological factors in radical prostatectomy material in Turkish prostate cancer patients: a multicenter study of the Urooncology Association.
        Prostate Int. 2020; 8: 10-15
        • Benjamini Y
        • Hochberg Y.
        Controlling the false discovery rate - a practical and powerful approach to multiple testing.
        J Royal Statist Soc, Series B. 1995; 57: 289-300
        • Murphy A
        • Carbunaru S
        • Nettey O
        • et al.
        A 17-Gene panel genomic prostate score has similar predictive accuracy for adverse pathology at radical prostatectomy in African american and european American men.
        Urology. 2020; : 142
        • Murphy AB
        • Abern MR
        • Liu L
        • et al.
        Impact of a genomic test on treatment decision in a predominantly african american population with favorable-risk prostate cancer: a randomized trial.
        J Clin Oncol. 2021; JCO2002997
        • Eure G
        • Germany R
        • Given R
        • et al.
        Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort.
        Urology. 2017; 107: 67-75
        • Albala D
        • Kemeter MJ
        • Febbo PG
        • et al.
        Health economic impact and prospective clinical utility of oncotype dx genomic prostate score.
        Rev Urol. 2016; 18: 123-132
        • Canfield S
        • Kemeter MJ
        • Hornberger J
        • Febbo PG.
        Active surveillance use among a low-risk prostate cancer population in a large us payer system: 17-gene genomic prostate score versus other risk stratification methods.
        Rev Urol. 2017; 19: 203-212
        • D'Elia C
        • Cerruto MA
        • Cioffi A
        • Novella G
        • Cavalleri S
        • Artibani W.
        Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy.
        Mol Clin Oncol. 2014; 2: 1145-1149
        • Nguyen PL
        • Shin H
        • Yousefi K
        • et al.
        Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists.
        Urology. 2015; 86: 35-40
        • Creed JH
        • Berglund AE
        • Rounbehler RJ
        • et al.
        Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk.
        Cancer Epidemiol Biomark & Prevent. 2020; 29: 246-253
        • Shen X
        • Pettaway CA
        • Chen RC.
        Active surveillance for black men with low-risk prostate cancer.
        JAMA. 2020; 324: 1733-1734